New COPD drug candidate shows promise in early trial

NCT ID NCT05516316

Completed Disease control Sponsor: EpiEndo Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested whether EP395, an oral capsule, can reduce lung inflammation in healthy adults. All 49 participants inhaled a substance that causes temporary airway inflammation, mimicking a key feature of COPD. Researchers measured inflammation levels and collected safety data to see if EP395 works better than a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EP395 (oral capsule)
What this could lead to: If it works, this could point toward a treatment that reduces lung inflammation in people with COPD.
What could go wrong: This is a very early Phase 1 trial in only 49 healthy adults, not COPD patients. The lung inflammation was artificially induced, so results may not translate to real-world COPD. The drug may also have side effects not yet seen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD

Contacts and locations

Locations

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Hanover, 30625, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.